Mars B. van ’t Veer

2.4k citations

36 papers · 1.4k indexed · 1 hit paper · h-index 15

Pathology and Forensic Medicine top 2%
Oncology top 10%
Cardiology and Cardiovascular Medicine top 5%
Hematology top 5%
Genetics top 5%

Co-authors: Berthe M.P. Aleman Marie L. De Bruin Flora E. van Leeuwen Alexandra W. van den Belt‐Dusebout Willem J. Klokman Harry Bartelink Jan Paul de Boer Augustinus A. M. Hart
Topics: Lymphoma Diagnosis and Treatment (15 papers)Chronic Lymphocytic Leukemia Research (9 papers)Acute Lymphoblastic Leukemia research (6 papers)
Cited by: Pathology and Forensic Medicine Genetics Hematology
Journals: Journal of Clinical Investigation Blood Annals of Neurology
Partner nations: Netherlands Poland United Kingdom

In The Last Decade

Mars B. van ’t Veer

36 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Late cardiotoxicity after treatment for Hodgkin lymphoma

2006 532 citations Berthe M.P. Aleman, Alexandra W. van den Belt‐Dusebout et al. Blood profile →

Peers

Countries citing papers authored by Mars B. van ’t Veer

Since Specialization

Citations

This map shows the geographic impact of Mars B. van ’t Veer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mars B. van ’t Veer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mars B. van ’t Veer more than expected).

Fields of papers citing papers by Mars B. van ’t Veer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mars B. van ’t Veer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mars B. van ’t Veer. The network helps show where Mars B. van ’t Veer may publish in the future.

Co-authorship network of co-authors of Mars B. van ’t Veer

This figure shows the co-authorship network connecting the top 25 collaborators of Mars B. van ’t Veer. A scholar is included among the top collaborators of Mars B. van ’t Veer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mars B. van ’t Veer. Mars B. van ’t Veer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Leukaemia update. Part 1: diagnosis and management 2013 ·BMJ ·Nicholas F. Grigoropoulos,Russell C. Petter,Mars B. van ’t Veer,Mike Scott,George Follows	14
2	Leukaemia update. Part 2: managing patients with leukaemia in the community 2013 ·BMJ ·(unknown),Russell C. Petter,Mars B. van ’t Veer,Mike Scott,George Follows	1
3	High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies 2011 ·British Journal of Haematology ·Elaine Boyd,Anthony J. Bench,Mars B. van ’t Veer,Penny Wright,David Bloxham,George Follows,Mike Scott	55
4	Roles of Radiation Dose and Chemotherapy in the Etiology of Stomach Cancer as a Second Malignancy 2009 ·International Journal of Radiation OncologyBiologyPhysics ·Alexandra W. van den Belt‐Dusebout,Berthe M.P. Aleman,(unknown),Marie L. De Bruin,Michael Hauptmann,Mars B. van ’t Veer,Ronald de Wit,J. G. Ribot,Evert M. Noordijk,J. Martijn Kerst,Jourik A. Gietema,Flora E. van Leeuwen	63
5	Malignant mesothelioma after radiation treatment for Hodgkin lymphoma 2009 ·Blood ·Marie L. De Bruin,Jacobus A. Burgers,Paul Baas,Mars B. van ’t Veer,Evert M. Noordijk,Marieke W.J. Louwman,Josée M. Zijlstra,Hendrik Van den Berg,Berthe M.P. Aleman,Flora E. van Leeuwen	49
6	Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison 2008 ·Blood ·Jan J. Cornelissen,Bronno van der Holt,Gregor Verhoef,Mars B. van ’t Veer,Marinus H. J. van Oers,Harry C. Schouten,Gert J. Ossenkoppele,Pieter Sonneveld,Johan Maertens,Marinus van Marwijk Kooy,M Schaafsma,Pierre W. Wijermans,Douwe H. Biesma,Shulamit Wittebol,P.J. Voogt,Joke W. Baars,Pierre Zachée,Leo F. Verdonck,Bob Löwenberg,A. W. Dekker	121
7	A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma 2007 ·Annals of Oncology ·Franck Morschhauser,John F. Seymour,Hanneke C. Kluin‐Nelemans,Andrew Grigg,M. Wolf,Michael Pfreundschuh,Hervé Tilly,(unknown),Mars B. van ’t Veer,Nöel Milpied,Guillaume Cartron,Antonio Pezzutto,Andrew Spencer,F Reyes,Martin Dreyling	88
8	Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial 2007 ·Blood ·Edo Vellenga,Wim L.J. van Putten,Mars B. van ’t Veer,Josée M. Zijlstra,Willem E. Fibbe,Marinus H. J. van Oers,Leo F. Verdonck,Pierre W. Wijermans,Gustaaf W. van Imhoff,Pieternella J. Lugtenburg,Peter C. Huijgens	131
9	CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B‐CLL): Comparison of three approaches to analyze its expression 2006 ·Cytometry Part B Clinical Cytometry ·Joke G. Boonstra,Kirsten van Lom,Anton W. Langerak,Wilfried J. Graveland,Peter J.M. Valk,Jaco Kraan,Mars B. van ’t Veer,Jan W. Gratama	35
10	Resolution of EBV⁺ CNS lymphoma with appearance of CSF EBV‐specific T cells 2005 ·Annals of Neurology ·(unknown),(unknown),Martin J. van den Bent,Mars B. van ’t Veer,G J van Doornum,Jan J. Cornelissen,Peter A. Sillevis Smitt,Jan W. Gratama	4
11	Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma 2005 ·Leukemia ·Gustaaf W. van Imhoff,Bronno van der Holt,Marius MacKenzie,G.J. Ossenkoppele,P. W. Wijermans,Mark H.H. Kramer,Mars B. van ’t Veer,Harry C. Schouten,Marinus van Marwijk Kooy,Marinus H. J. van Oers,John Raemaekers,Pieter Sonneveld,(unknown),P.M. Kluin,Hanneke C. Kluin‐Nelemans,Leo F. Verdonck	30
12	Immune and nonimmune causes of low recovery from leukodepleted platelet transfusions: a prospective study 2003 ·Annals of Hematology ·Mark‐David Levin,(unknown),Bronno van der Holt,Mars B. van ’t Veer	7
13	Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy 2001 ·Radiotherapy and Oncology ·Augustinus D. G. Krol,(unknown),(unknown),Sonja C. Henzen‐Logmans,Bronno van der Holt,Mars B. van ’t Veer	15
14	Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH− subgroup of multiple myeloma 2000 ·Blood ·Tomasz Szczepański,Mars B. van ’t Veer,Ingrid L. M. Wolvers‐Tettero,Anton W. Langerak,Jacques J. M. van Dongen	1
15	Platelet‐bound immunogloblins before and after platelet transfusion: measurement of in vivo binding 1999 ·British Journal of Haematology ·(unknown),W. de Vries,(unknown),(unknown),Bronno van der Holt,Mars B. van ’t Veer	10
16	Pitfalls in the immunophenotyping of leukaemia and leukaemic lymphomas: survey of 9 years of quality control in The Netherlands 1996 ·British Journal of Haematology ·Hanneke C. Kluin‐Nelemans,Elisabeth R. van Wering,Mars B. van ’t Veer,C. Ellen van der Schoot,H. J. Adriaansen,(unknown),Jan W. Gratama	12
17	Two hours iv infusion of 2-chlorodeoxyadenosine (2-CDA) in hairy cell leukemia (HCL) is effective and may produce less CD34/CD8 ratio impairment. Results from the HOVON-23 study 1995 ·Blood ·John Raemaekers,Mars B. van ’t Veer,(unknown),P.C. Huijgens,(unknown),Rien H. J. Van Oers,(unknown),(unknown)	2
18	AML-M0: clinical entity or waste basket for immature blastic leukemias? A description of 14 patients 1995 ·Annals of Hematology ·Christine M. Segeren,(unknown),Mars B. van ’t Veer	12
19	Translocation (6;9) may be associated with a specific TdT-positive immunological phenotype in ANLL. 1988 ·PubMed ·H. J. Adriaansen,Jacques J. M. van Dongen,Herbert Hooijkaas,K. Hählen,Mars B. van ’t Veer,Bob Löwenberg,(unknown)	24
20	Changes in the surface marker pattern related to maturation in adult acute myeloid leukaemia 1983 ·Leukemia Research ·D.J. van Rhenen,(unknown),Mars B. van ’t Veer,C. P. Engelfriet,(unknown),M. M. A. C. Langenhuijsen	8

About Mars B. van ’t Veer

Mars B. van ’t Veer is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine, having authored 36 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Acute Lymphoblastic Leukemia research (6 papers). The work is most often cited by research in Pathology and Forensic Medicine (536 citations), Genetics (284 citations) and Hematology (292 citations). Mars B. van ’t Veer has collaborated with scholars based in Netherlands, Poland and United Kingdom. Frequent co-authors include Berthe M.P. Aleman, Marie L. De Bruin, Flora E. van Leeuwen, Alexandra W. van den Belt‐Dusebout, Willem J. Klokman, Harry Bartelink, Jan Paul de Boer, Augustinus A. M. Hart, Margreet H.A. Baaijens and Marianne A. Kuenen. Their work appears in journals such as Journal of Clinical Investigation, Blood and Annals of Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact